CordenPharma's Standard Lipid Catalog List

CordenPharma has submitted its near-term greenhouse gas (GHG) emission reduction targets to the Science Based Targets initiative (SBTi) for approval, marking a major step in its climate action commitments.
 

Register for this Live (4-4-18) or on Demand webinar to learn how the most important (and often over-looked) aspect to a robust containment program is the strength of the intangible, softer elements. Discuss how to maximize the success of your engineering control investments and allow for continued alignment to your company’s commitment to providing a workplace free of recognized health & safety hazards.

CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities. 

This recorded webinar archive addresses the necessity of serialization from market compliance to business supply. Expert speaker Mario Scigliano covers all aspects of serialization, from line choice and regulation approach to management of data and related products.

The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. 

For generic drug companies, CordenPharma supplies more than 50 Active Pharmaceutical Ingredients (APIs), including controlled substances, for pain management, cardiovascular, gastrointestinal, central nervous system, anti-infective and respiratory indications. We manufacture these products using complex and technical expertise while maintaining a long-standing reputation of quality and reliability.

In this interview from CPHI Frankfurt 2022, we speak to Dr Michael Quirmbach of CordenPharma about his role as President and CEO and what CordenPharma is bringing to the pharma industry.

CordenPharma offers a wide selection of Readily Available Derivatized Phospholipids suitable for Research & Discovery for purchase in convenient 1 g and 10 g pack sizes.

2 May 2022 – Basel >

Astorg and International Chemical Investors Group (“ICIG”) today announce that they have signed a binding agreement whereby Astorg will acquire CordenPharma (“CordenPharma” or the “Company”), a global leading pharmaceutical CDMO (Contract Development & Manufacturing Organisation) with highly differentiated capabilities in Active Pharmaceutical Ingredients, Excipients, and Drug Products, from ICIG.

Speakers: Mark Chipperfield (Corvus Ltd), Fabio Stevanon (CordenPharma), Umberto Romeo (CordenPharma)
Key Learning Objectives:
Review the fundamentals of combined injectable delivery device - drug products. Get an update on the latest regulation landscape for combined drug-device products, including some technical challenges for injectable Pre-Filled Syringes (PFS) & Auto-injectors. Gain insight into sound Injectable Drug Product strategy from a Full-Service CDMO industry leader. Learn about recent injectable industry changes facing Pharma, especially in the “New Normal” COVID-19 era, and how CordenPharma’s successful response & expanded capabilities can best support your drug development goals. Learn from an R&D Expert on ways to efficiently develop & commercialize an injectable drug.

1 February 2022 – Luxembourg > CordenPharma, a leading, full-service Contract Development & Manufacturing Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities from Vifor Pharma, to be ultimately renamed Corden Pharma Fribourg S.A. (including its Ettingen branch) in Switzerland, and Corden Pharma Lisbon S.A. in Portugal.

Your Injectable Roadmap for Combined Drug Product - Delivery Device Regulations & Evolving Capabilities in the New Normal > How a Full-Service CDMO Supports Pharma

Luxembourg, 19 April 2021 -- In response to the COVID-19 pandemic, mRNA (messenger RNA) vaccines have catapulted to center stage of the pharmaceutical and biotechnology industry. As of early 2021, there are eight ongoing human trials for mRNA vaccines led by Moderna, BioNTech / Pfizer, CureVac, Sanofi / TranslateBio, Arcturus / Duke-NUS Medical School (Singapore), Imperial College London, Chulalongkorn University (Thailand), and Providence Therapeutics.

WeylChem InnoTec are your innovative partner to the fine chemical, pharmaceutical and electronic industry. We provide world-class analytical, modern developmental and tailor-made manufacturing services. With our competencies in Analytics, Contract Development & Custom Synthesis, WeylChem InnoTec is your agile development partner.

Our Services:AnalyticsContract DevelopmentCustom SynthesisAdvanced technologies
How We Support You in Different Markets:
Organic ElectronicsCatalysts and LigandsSustainable ChemistryPharmaceutical IntermediatesAgrochemicalsVisit weylchem-innotec.com or email [email protected] for more information.

If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

As your ONE PARTNER, CordenPharma provides you with an integrated solution spanning all product life cycle stages, from preclinical to commercial, supported by dedicated regulatory and project management services.

11 April 2022 - Munich / Halle / Plankstadt

• WACKER AND CORDENPHARMA TO BECOME PART OF GERMANY’S PANDEMIC PREPAREDNESS PLANTHE TWO COMPANIES WILL BE READY TO PRODUCE MRNA VACCINES FOR THE GERMAN GOVERNMENT IF THE COVID-19 PANDEMIC CONTINUES OR A NEW PANDEMIC OCCURS
• WACKER AND CORDENPHARMA JOINTLY COVER THE ENTIRE MANUFACTURING CHAIN FOR VACCINES
• HALLE WILL BECOME A COMPETENCE CENTER FOR PRODUCING MRNA VACCINES, WITH ADDITIONAL CAPACITY FOR OTHER CUSTOMERS AS WELL
• CORDENPHARMA WILL USE ITS YEARS OF EXPERIENCE IN PRODUCING CUSTOM AND STANDARD LIPIDS AND IN FILL & FINISH
• WACKER INTENDS TO INVEST OVER €80 MILLION ANNUALLY IN EXPANDING THE GROWTH OF ITS BIOTECHNOLOGY BUSINESS OVER THE NEXT FEW YEARS

CordenPharma is making a record investment of ~€900m over the next 3 years in expanding its peptide platform, both at its Colorado, US site and in Europe.

Luxembourg, 28 May 2020 -- CordenPharma, a full-service Contract Development & Manufacturing Organization (CDMO) for the supply of APIs, Drug Products & Pharmaceutical Packaging, announces the signing of an amendment to their existing manufacturing agreement with Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients.

We offer sophisticated process development addressing critical process parameters & quality attributes to deliver the most suitable crystalline form of an API.

Custom & standard lipids manufacturing, including lipids for mRNA-based therapeutics, Lipid NanoParticle Starter kits & integrated Formulation / Fill & Finish.

Receive quarterly updates on CordenPharma's latest strategic investments & initiatives across all 6 technology platforms, as well as industry news & trends.

2023 marked the start of our campaign to evaluate & develop science-based targets for reducing greenhouse gas emissions in line with the SBTi initiative.

Project to accelerate use of AI algorithm to develop new generation of Lipid NanoParticles (LNPs), as key components of RNA-based drugs, with best formulations.

CordenPharma's new TSAB includes 8 world-class experts from academia & industry, who will provide strategic & scientific expertise to drive continued growth.

CordenPharma enters the synthetic oligonucleotide manufacturing arena with capex investment in two phases and fully-integrated APIs to Drug Product offerings.

CordenPharma inaugurates increased commercial peptide production with newly-upgraded facilities in Colorado, the largest SPPS manufacturing capacity worldwide.

Drug product development & manufacturing for OSD and other non-sterile specialty dosage forms, and Aseptic / Terminal sterile dosage forms for all stages.

CordenPharma is an expert in contract manufacturing & packaging of various dosage forms with primary/secondary technologies from early-stage to commercial.

Generic APIs offered across multiple CordenPharma facilties.

CordenPharma’s early-phase Drug Product services & bioavailability enhancement address formulations containing solubility- or permeability-challenged APIs.

With over 12,000 L of capacity and reactors up to 28,000 L, we manufacture your API & 100s of millions of tablets/capsules with various formulation options.

The Highly Potent & Oncology platform offers potent compounds with API scale-up from lab to 12,000 L vessels and OSD manufacturing starting from 100 g blend.

The Oligonucleotide platform supplies you with specialized combined expertise from early stage to commercial supply of advanced Oligonucleotide APIs.

Our injectable services start from early formulation development to full commercial scale, covering both terminal sterilization & aseptic filling, including PFS

The Backbone of Synthesis – Advanced Peptide APIs > Our scientists have mastered the synthesis of peptide APIs from early phase development to large-scale.

Video highlighting CordenPharma as your ONE PARTNER CDMO for the fully-integrated supply of APIs, Excipients, Drug Products and Packaging across 5 Technology Platforms:InjectablesHighly Potent & OncologySmall MoleculesPeptidesLipids & Carbohydrates

cGMP API Manufacturing in Bergamo, IT

cGMP API Manufacturing in Brussels, BE

Since 2021 marks the 15 Year Anniversary of CordenPharma, we take a look back to our founding in 2006 with videos highlighting each of our API & Drug Product facility acquisitions that together, formed the foundation of our integrated supply network across Europe & the US. Thus began the journey of transforming former Large Pharma & Biotech assets into a ONE PARTNER CDMO.

Small Molecule and Lipid Excipient Manufacturing in Liestal, CH

Highly Potent Drug Product Manufacturing in Plankstadt, DE

Peptide R&D Non-GMP Manufacturing in Frankfurt, DE

Peptide, Lipid Excipient and Highly Potent API Manufacturing in Boulder, CO, USA

API and Lipid Excipient Manufacturing in Chenove, FR.

Sterile Injectable Drug Product Manufacturing in Caponago, IT